Philipp Martin advises prominent financial sponsors and corporates on cross-border M&A transactions, predominantly in the business services, technology, and industrial sectors. He represents clients on investments in private and public companies, joint ventures, co- and re-investments, management participation programs, and preferred equity or hybrid investments. His also provides strategic legal advice on corporate law matters, and he gained significant in-house experience during a secondment to the investment legal team of a European large cap private equity house.
Prior to joining Jones Day in 2025, Philipp represented Riverside on the investment into GFOS, a software provider in the areas of workforce management, access control, and manufacturing execution systems; Nimbus Private Equity on the sale of Extrusion Technology Group to Gamut Capital's portfolio company Davis-Standard; Brookfield Asset Management on the intended acquisition of a testing and inspection business in the oil and gas infrastructure space; a consortium comprising of Life Sciences Partners (now EQT Life Sciences), HealthCap, and Pureos Bioventures on the carve-out of Ariceum Therapeutics from pharma company Ipsen; Charterhouse Capital Partners on the acquisition of telecommunications company Telio Management from DBAG; Advent International on the sale of allnex group to PTT Global Chemical; APAX Partners on various matters, including the acquisition of WSGN from Ascential; and Centerbridge on several matters, including Auxmoney and the intended acquisition of a stake in Norddeutsche Landesbank.
- Upper Regional Court Frankfurt (Second State Examination 2021); Goethe University Frankfurt (First State Examination 2018)
- Federal Republic of Germany
- English and German
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice